20S proteasome beta-5 subunit (PSMB5), beta-1 subunit (PSMB6), and beta-1i subunit (PSMB9) (PSMB5/PSMB6/PSMB9)

The 20S proteasome is the catalytic core of the 26S proteasome complex, a multi-subunit protease responsible for the degradation of polyubiquitinated proteins in eukaryotic cells (UniProt P28074). It contains three primary catalytic sites: the chymotrypsin-like (beta-5), caspase-like (beta-1), and trypsin-like (beta-2) subunits. In response to inflammatory signals, constitutive subunits are replaced by immunoproteasome subunits, such as beta-1i (LMP2), which alter the peptide cleavage pattern for MHC class I antigen presentation (UniProt P28065). Therapeutic targeting of the beta-5 subunit is a validated strategy for treating plasma cell dyscrasias, as these cells are highly dependent on proteasome function to manage high protein synthesis rates. Additional inhibition of the beta-1 and beta-1i subunits, as seen with drugs like carfilzomib at higher concentrations, can provide more robust suppression of proteasomal activity and potentially overcome resistance to beta-5-selective inhibitors (PMID: 21896830). However, broader inhibition of multiple subunits is often associated with increased systemic toxicity, including cardiovascular and neurological adverse effects (StatPearls NBK542314).

Other names

Proteasome subunit beta type-5PSMB5Chymotrypsin-like subunitProteasome subunit beta type-1PSMB6Caspase-like subunitProteasome subunit beta type-9PSMB9LMP2Immunoproteasome subunit beta-1i20S proteasome

Covalent or non-covalent inhibition of the N-terminal threonine residues of the 20S proteasome catalytic subunits, leading to the accumulation of polyubiquitinated proteins, induction of the unfolded protein response, and subsequent apoptosis (PMID: 21896830).